IMV Strengthens Its Financial Position With the Completion of a US$25 Million Long-Term Debt Facility

DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass. — IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and hematological cancers, today announced the completion of a US$25 million long-term debt facility led by Horizon Technology Finance Corporation (Nasdaq: HRZN) (“Horizon”). IMV has drawn down US$15 million with an additional US$10 million to be made available upon achievement of a pre-set milestone. Read More